Your browser doesn't support javascript.
loading
Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment.
Ruiz-Limon, Patricia; Barbarroja, Nuria; Perez-Sanchez, Carlos; Aguirre, Maria Angeles; Bertolaccini, Maria Laura; Khamashta, Munther A; Rodriguez-Ariza, Antonio; Almadén, Yolanda; Segui, Pedro; Khraiwesh, Husam; Gonzalez-Reyes, Jose Antonio; Villalba, Jose Manuel; Collantes-Estevez, Eduardo; Cuadrado, Maria Jose; Lopez-Pedrera, Chary.
Afiliação
  • Ruiz-Limon P; Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain.
  • Barbarroja N; Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain.
  • Perez-Sanchez C; Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain.
  • Aguirre MA; Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain.
  • Bertolaccini ML; Graham Hughes Lupus Research Laboratory, The Rayne Institute, King's College London, London, UK.
  • Khamashta MA; Graham Hughes Lupus Research Laboratory, The Rayne Institute, King's College London, London, UK.
  • Rodriguez-Ariza A; Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain.
  • Almadén Y; Lipid and Atherosclerosis Unit, IMIBIC/Reina Sofia University Hospital/University of Córdoba, CIBER Fisiopatología Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.
  • Segui P; Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain.
  • Khraiwesh H; University of Cordoba, Campus de Excelencia Internacional Agroalimentario, Cordoba, Spain.
  • Gonzalez-Reyes JA; University of Cordoba, Campus de Excelencia Internacional Agroalimentario, Cordoba, Spain.
  • Villalba JM; University of Cordoba, Campus de Excelencia Internacional Agroalimentario, Cordoba, Spain.
  • Collantes-Estevez E; Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain.
  • Cuadrado MJ; Graham Hughes Lupus Research Laboratory, The Rayne Institute, King's College London, London, UK.
  • Lopez-Pedrera C; Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain.
Ann Rheum Dis ; 74(7): 1450-8, 2015 Jul.
Article em En | MEDLINE | ID: mdl-24658835
ABSTRACT

OBJECTIVE:

Statins may have beneficial vascular effects in systemic lupus erythematosus (SLE) beyond their cholesterol-lowering action, although the mechanisms involved are not completely understood. We investigated potential mechanisms involved in the efficacy of fluvastatin in preventing atherothrombosis in SLE.

METHODS:

Eighty-five patients with SLE and 62 healthy donors were included in the study. Selected patients (n=27) received 20 mg/day fluvastatin for 1 month. Blood samples were obtained before the start and at the end of treatment. Monocytes from five patients were treated in vitro with fluvastatin.

RESULTS:

Increased prothrombotic and inflammatory variables were found in patients with SLE. SLE monocytes displayed altered mitochondrial membrane potential and increased oxidative stress. Correlation and association analyses demonstrated a complex interplay among autoimmunity, oxidative stress, inflammation and increased risk of atherothrombosis in SLE. Fluvastatin treatment of patients for 1 month reduced the SLE Disease Activity Index and lipid levels, oxidative status and vascular inflammation. Array studies on monocytes demonstrated differential expression in 799 genes after fluvastatin treatment. Novel target genes and pathways modulated by fluvastatin were uncovered, including gene networks involved in cholesterol and lipid metabolism, inflammation, oxidative stress and mitochondrial activity. Electron microscopy analysis showed increased density volume of mitochondria in monocytes from fluvastatin-treated patients, who also displayed higher expression of genes involved in mitochondrial biogenesis. In vitro treatment of SLE monocytes confirmed the results obtained in the in vivo study.

CONCLUSIONS:

Our overall data suggest that fluvastatin improves the impairment of a redox-sensitive pathway involved in processes that collectively orchestrate the pathophysiology of atherothrombosis in SLE.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Aterosclerose / Lúpus Eritematoso Sistêmico Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Rheum Dis Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Aterosclerose / Lúpus Eritematoso Sistêmico Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Rheum Dis Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Espanha